about
SAM68: Signal Transduction and RNA Metabolism in Human CancerRegulation of the Ras-MAPK and PI3K-mTOR Signalling Pathways by Alternative Splicing in CancerThe alternative splicing factor Nova2 regulates vascular development and lumen formation.hnRNP L inhibits CD44 V10 exon splicing through interacting with its upstream intronCell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene.A single polypyrimidine tract binding protein (PTB) binding site mediates splicing inhibition at mouse IgM exons M1 and M2.A 2-nt RNA enhancer on exon 11 promotes exon 11 inclusion of the Ron proto-oncogene.Posttranscriptional Regulation and RNA Binding Proteins in Cancer BiologySRSF2 promotes splicing and transcription of exon 11 included isoform in Ron proto-oncogene.Transcription of Satellite III non-coding RNAs is a general stress response in human cellsAlternative splicing and muscular dystrophy.Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy.Making alternative splicing decisions during epithelial-to-mesenchymal transition (EMT).The alternative splicing side of cancer.EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression.Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives.Growth-dependent and growth-independent translation of messengers for heterogeneous nuclear ribonucleoproteins.Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene.Alternative splicing: role in cancer development and progression.Diversification of the muscle proteome through alternative splicing.A novel L1CAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicingAltered expression of heterogenous nuclear ribonucleoproteins and SR factors in human colon adenocarcinomasGene Expression Profiles Controlled by the Alternative Splicing Factor Nova2 in Endothelial Cells
P50
Q26798149-60329EFF-AC21-4708-99EE-811897195795Q27001635-4B46D537-C8F4-44E7-85FF-825E8520A669Q27321847-2F6B835E-B62C-4702-B6AC-B435F48A5075Q28114906-CE162445-1606-4208-873A-22F15F6F513DQ33992355-21E6D075-A118-4890-943E-98AC0E7CFE73Q34365702-73DF4C89-44F0-490C-868E-62BC7C7F83CDQ35926343-40EAEC0E-7094-4EDF-99B7-C4CB05C10F8FQ35932172-705CC48A-1FF4-43F5-B530-121B421CCA47Q35949901-95CEDB8D-B32A-44F5-9F0E-7997439CB270Q36457069-28FDE539-160F-423D-A026-B5D2096525D7Q36599506-963B4B9B-A9A9-4E70-9351-8650114F431FQ37304724-19C0EB0F-1A81-4B8D-BFE2-EDE7C7D4BF03Q37986326-F18851D9-B4D5-441E-B662-06FC1503DB6DQ38198391-3B5E75D3-ED63-40E6-957B-E51691D4E8C2Q39109931-4046FCE3-F52B-4522-A77C-C9746BD1F585Q39652134-E6B05C9A-5271-44C9-9F0B-50A62156ECB1Q39721230-53A5F56F-AF9A-4618-B2FA-682A02A2D836Q42008721-AA46E275-1622-405C-A178-60204CD4D94BQ42842154-71921519-CCA0-4575-B8D7-26735C03A623Q52671372-A8B83171-8A33-4BFA-8453-A040572AC40CQ63406959-500C84E3-C93C-4936-999F-5FDBA9CA1400Q77726451-B1775FCB-7B83-40E2-B0EF-202E615E2454Q91468633-43325F52-A75A-480F-85AC-DF19162A2C78
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Claudia Ghigna
@ast
Claudia Ghigna
@en
Claudia Ghigna
@es
Claudia Ghigna
@nl
Claudia Ghigna
@sl
type
label
Claudia Ghigna
@ast
Claudia Ghigna
@en
Claudia Ghigna
@es
Claudia Ghigna
@nl
Claudia Ghigna
@sl
prefLabel
Claudia Ghigna
@ast
Claudia Ghigna
@en
Claudia Ghigna
@es
Claudia Ghigna
@nl
Claudia Ghigna
@sl
P106
P1153
6506967502
P21
P31
P496
0000-0003-0362-783X